IPOS
9706129-5

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/135 — A1

(11) International Publication Number: **WO 97/02026**

(43) International Publication Date: 23 January 1997 (23.01.97)

(21) International Application Number: PCT/EP96/02970

(22) International Filing Date: 5 July 1996 (05.07.96)

(30) Priority Data:
9513750.1 6 July 1995 (06.07.95) GB

(71) Applicant *(for all designated States except AT DE US)*: SANDOZ LTD. [CH/CH]; Lichtstrasse 35, CH-4002 Basle (CH).

(71) Applicant *(for DE only)*: SANDOZ-PATENT-GMBH [DE/DE]; Humboldtstrasse 3, D-79539 Lörrach (DE).

(71) Applicant *(for AT only)*: SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: LINDLEY, Ivan, James, Dalton [GB/AT]; Anton-Seidlgasse 23, A-2345 Brunn/Gebirge (AT). RYDER, Neil, Stewart [GB/AT]; Donizettigasse 5, A-1220 Vienna (AT).

(74) Common Representative: SANDOZ LTD.; Patents & Trademarks Division, Lichtstrasse 35, CH-4002 Basle (CH).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
With amended claims and statement.

(54) Title: USE OF ALLYLAMINE DERIVATIVES SUCH AS TERBINAFINE, IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTION OF ASSOCIATED DISEASES

(57) Abstract

Use of compounds of formula (I), wherein R has various significances, in free base form or in pharmaceutically acceptable salt form, as agents against H. pylori infection and associated diseases.



(I)